761 related articles for article (PubMed ID: 2703964)
1. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.
Norman AB; Eubanks JH; Creese I
J Pharmacol Exp Ther; 1989 Mar; 248(3):1116-22. PubMed ID: 2703964
[TBL] [Abstract][Full Text] [Related]
2. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates.
Lee JH; el-Fakahany EE
J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cardiac muscarinic receptors recognized selectively by nonquaternary but not by quaternary ligands.
Brown JH; Goldstein D
J Pharmacol Exp Ther; 1986 Aug; 238(2):580-6. PubMed ID: 3016242
[TBL] [Abstract][Full Text] [Related]
5. Positive cooperativity in the binding of alcuronium and N-methylscopolamine to muscarinic acetylcholine receptors.
Tucek S; Musílková J; Nedoma J; Proska J; Shelkovnikov S; Vorlícek J
Mol Pharmacol; 1990 Nov; 38(5):674-80. PubMed ID: 2233700
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of alkylating agents on the multiple muscarinic receptor subtypes linked to activation of phospholipase C by carbachol in rat brain cortical membranes.
Sallés J; Wallace MA; Fain JN
J Pharmacol Exp Ther; 1993 Feb; 264(2):521-9. PubMed ID: 8437104
[TBL] [Abstract][Full Text] [Related]
7. Influence of ligand choice on the apparent binding profile of gallamine to cardiac muscarinic receptors. Identification of three main types of gallamine-muscarinic receptor interactions.
Lee NH; el-Fakahany EE
J Pharmacol Exp Ther; 1988 Sep; 246(3):829-38. PubMed ID: 3418516
[TBL] [Abstract][Full Text] [Related]
8. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
9. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
10. Recognition of muscarinic cholinergic receptors in human SK-N-SH neuroblastoma cells by quaternary and tertiary ligands is dependent upon temperature, cell integrity, and the presence of agonists.
Fisher SK
Mol Pharmacol; 1988 Apr; 33(4):414-22. PubMed ID: 3357485
[TBL] [Abstract][Full Text] [Related]
11. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain.
Flynn DD; Mash DC
Synapse; 1993 Aug; 14(4):283-96. PubMed ID: 8248852
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled by [3H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists.
Gillard M; Waelbroeck M; Christophe J
Mol Pharmacol; 1987 Jul; 32(1):100-8. PubMed ID: 3600611
[TBL] [Abstract][Full Text] [Related]
13. Evidence of paired M2 muscarinic receptors.
Potter LT; Ballesteros LA; Bichajian LH; Ferrendelli CA; Fisher A; Hanchett HE; Zhang R
Mol Pharmacol; 1991 Feb; 39(2):211-21. PubMed ID: 1899905
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium.
Dunlap J; Brown JH
Mol Pharmacol; 1983 Jul; 24(1):15-22. PubMed ID: 6135150
[TBL] [Abstract][Full Text] [Related]
16. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
17. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
18. M1 and M3 muscarinic receptor subtypes in rat forebrain.
Pavia J; Marquez E; Laukkonen S; Martos F; Gómez A; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1991 Dec; 13(10):653-60. PubMed ID: 1770828
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of muscarinic receptors on rat pancreatic acini by using 125I-quinuclidinyl benzilate and N-[3H]-methylscopolamine].
Aoki E; Adachi H; Noguchi M; Satoh S; Ohnishi S; Honda T; Konishi J
Nihon Shokakibyo Gakkai Zasshi; 1991 Aug; 88(8):1571-8. PubMed ID: 1942611
[TBL] [Abstract][Full Text] [Related]
20. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
